Pfizer (PFE) Short term Debt (2009 - 2026)

Pfizer (PFE) has reported Short term Debt for 18 consecutive years, with $2.7 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Short term Debt fell 37.16% year-over-year to $2.7 billion in Q2 2026; TTM through Jun 2026 was $2.7 billion, a 37.16% decrease from a year earlier, with the FY2025 full-year figure at $3.2 billion, down 54.59% from the prior year.
• Short term Debt was $2.7 billion for Q2 2026 at Pfizer, down from $3.9 billion in the prior quarter.
• Over five years, Short term Debt peaked at $11.9 billion in Q2 2024 and troughed at $645.0 million in Q2 2022.
• A 5-year average of $5.5 billion and a median of $4.3 billion in 2025 frame the typical range for Short term Debt.
• Across the five-year window, Short term Debt slumped 85.18% in 2022 and soared 549.3% in 2023, its largest moves.
• Over 5 years, Short term Debt stood at $2.9 billion in 2022, then surged by 251.44% to $10.4 billion in 2023, then sank by 32.89% to $6.9 billion in 2024, then sank by 54.59% to $3.2 billion in 2025, then decreased by 14.43% to $2.7 billion in 2026.
• The last three Short term Debt figures came in at $2.7 billion (Q2 2026), $3.9 billion (Q1 2026), and $3.2 billion (Q4 2025), per Business Quant data.